Specifically, the modulation and expression of this crucial transcription factor on ECP treatment have been investigated exclusively within the framework of graft-versus-host disease.27-29 Thus, our findings extend previously published data, revealing that ECP therapy also improves the frequency of FoxP3+ Treg in HTx individuals. The gene discussed is FOXP3; the disease is graft versus host disease.